$AMGN Recent Headlines Cal-Maine Foods shares fall on

New Post Public Reply Private Reply Replies (0) Message Board

Dec 26, 2014 at 12:16 PM

$AMGN Recent Headlines

Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com

Stock Market News for December 26, 2014 - Market News 10:10 a.m. Today - Zacks.com
After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog 9:25 a.m. Today - Zacks.com
4 Biotech Stocks that Doubled in 2014 - Analyst Blog 9:00 a.m. Today - Zacks.com
I'm Waiting Till The Carnage In Biotech Stocks Subsides To Buy Amgen 7:53 a.m. Today - Seeking Alpha
Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog 5:10 p.m. Dec. 24, 2014 - Zacks.com
Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog 4:45 p.m. Dec. 24, 2014 - Zacks.com
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Biggest Movers in Healthcare Stocks Now – TARO LPNT THC GILD 1:30 p.m. Dec. 24, 2014 - InvestorPlace.com
Are There Any Winners Left In The Biotech Space? 12:01 p.m. Dec. 24, 2014 - benzinga.com
Stock Market News for December 24, 2014 - Market News 10:10 a.m. Dec. 24, 2014 - Zacks.com
Why I Expect The Biotech Sell-Off To Continue Into 2015 8:08 a.m. Dec. 24, 2014 - Seeking Alpha
Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog 5:00 p.m. Dec. 23, 2014 - Zacks.com
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog 4:30 p.m. Dec. 23, 2014 - Zacks.com
Amgen - Not Worth Buying At Its Elevated Valuation 10:10 a.m. Dec. 23, 2014 - Seeking Alpha
Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog 6:10 p.m. Dec. 22, 2014 - Zacks.com
AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst Blog 5:45 p.m. Dec. 22, 2014 - Zacks.com
AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst Blog 5:24 p.m. Dec. 22, 2014 - Zacks.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Dow Stars, Biotech Lead 13 Dividend Stocks Increasing Payouts 5:13 a.m. Dec. 22, 2014 - InvestorPlace.com

Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Legal Storm Over Misleading Investor Claims

Legal Troubles Mount for Innventure, Inc. Looks like Innventure, Inc. is caught in the kind of mess that even seasoned traders dread—a class action lawsuit hanging over its head like a storm cloud just bursting with lightning. If you're holding a piece of Innventure (NASDAQ: INV), this is one of those times when you've got to look your portfolio straight in the eye and...

Norwegian Bella™: A New Era in Luxury Cruising

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

DaVita's Stand on HHS Kidney Plan: Innovation at Core

DaVita Stands Firm on Kidney Care Innovation The healthcare landscape's shifting undercurrent, folks, and kidney care has landed smack in the spotlight with the U.S. Department of Health and Human Services (HHS) putting forth its Kidney Care National Plan. Now, this isn't some bureaucratic mumbo-jumbo—this plan's setting the tone for kidney disease treatment across...

LAZ Parking and indiGOtech's Bold EV Charging Move

EV Chargers: The Future Parked Closer? I've been around the block more times than a cabbie in Manhattan rush hour, and let me tell you, when it comes to EVs, folks are still playing catch-up. But here's a kicker—LAZ Parking and indiGOtech have decided they're not gonna wait around. This joint venture of theirs aims to sock some sense into the old condo complex parking...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

JinkoSolar Passes Key Resolutions Amid Name Change

A New Chapter for JinkoSolar Right out of the gate, JinkoSolar has decided to shake things up, along with a new legal identity. The news coming from their 2026 annual general meeting confirms a significant shift in branding from ‘JinkoSolar Holding Co., Ltd’ to the new title of ‘Jinko Holdings Limited’. If you’ve been around the block like me, you’ll know that...

ALS.Community Launches Free Online Support Platform

A Long Path to Connection Sometimes it's easy to forget the power a community can wield until you see one rally around a cause. The launch of ALS.Community isn't just a digital debut; it's a testament to how collective understanding can be a lifeline. For folks grappling with amyotrophic lateral sclerosis (ALS), beating solitude is often half the battle. Founder Jeff...

Sunrate and TourMind Partner to Boost Travel Payments

Travel Sector Eyes Major Payment Makeover Sunrate and TourMind are shaking hands in a big way, capitalizing on the blurring lines between digital connectivity and global travel demands. Their union is the latest bid to tackle financial snags and streamline operations in this ever-evolving market. I mean, who isn't fed up with clunky payment systems when jet-setting across...

Software Tax Hits Enterprises: Costly Control Concerns

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

Network Brainiacs Expands Footprint into Maryland Market

Network Brainiacs Steps into Maryland Territory If you're in the tech services game, expansion stories are the bread and butter of this business. Network Brainiacs, a seasoned veteran in the managed IT and cybersecurity sectors, has taken their first big step into Maryland by acquiring Computer Enhancement Systems (CES), a notable player in the field, as of September 1,...